Kuijjer Lab

Daniel receives funding from Familien Blix Fond

November 30, 2021

We're thrilled to announce that Daniel has received funding from Familien Blix Fond on the project "Quinolinate Phosphoribosyltransferase (QPRT) as a target gene for the reduction of resistance development in ER-positive breast cancer." This project will allow us to validate computational predictions on a gene that is potentially involved in resistance to tamoxifen, which Daniel recently found through in silico knock-down experiments in breast cancer. We will be collaborating with Xavier Tekpli and Salim Ghannoum from Oslo University Hospital. NCMM put together a news article about the project that can be accessed here.

Preliminary results include comparing gene expression (A) and variability (B) profiles from a breast cancer cell line with ER+ epithelial cells obtained from single-cell sequencing experiments, the detection of consistent highly variable genes (C), and identification of uniformly expressed regulators of these highly variable genes through an in silico knock-down screen (D). QPRT is a top candidate that relatively stably expressed (E), but at the same time a prognostic gene in breast cancer (F).

Powered by Jekyll